… in the COVID-19 pathogenicity. Furthermore, we focused on possible therapeutic options
such … It was used as inhibitor of nanoparticles uptake via endocytosis pathway. Similar kind of …

… pathways but not fusional ones, for example hydroxychloroquine would be ineffective for the
treatment of COVID-19. In … Discovery of a novel inhibitor of coronavirus 3CL protease as a …

… by COVID-19 and SARS-CoV, targeted blocking drugs against ACE2, and drugs that inhibit
… target organ for COVID-19 infection, but whether digestive system is a route of transmission …

… and in 33 (18%) of 179 patients receiving TCZ (p = 0.41), regardless of drug formulation (18%
for intravenous and 19% for subcutaneous route). Fatal outcomes were observed in 20% …

… (RAS) pathway. ACE2 acts in the renin-angiotensin-aldosterone system (RAS) as an inhibitor
of angiotensin II and its downstream effects. As a negative regulator of the pathway, ACE2 …

… COVID-19 employ a distinct intracellular signaling pathway mediated by Janus kinases (JAKs).
JAK inhibition, therefore, presents an attractive therapeutic … outcomes in COVID-19. Below…

… 1, a set of inhibitory molecules (TRAIL, programmed cell death … COVID-19. Notably, the
decreased expression of NKG2A and number of CD8+ and NK cells were restored after therapies …

… the mTOR pathway in diverse cellular processes, it is not surprising that this pathway shapes
the … research also supports the therapeutic potential of mTOR inhibitors against COVID-19. …

… considered the new avenue for the treatment of COVID-19. … thorough intravenous route)
with other supportive therapy in … protease inhibition by protease inhibitors used in HIV therapy …

… about the potential use of baricitinib for severe acute respiratory syndrome coronavirus 2 (SARS-…
therapy is an undeniable advantage over other potential inhibitors of the same pathway. …